|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance increases expression |
ISO |
ABCB1 polymorphism affects the susceptibility to Warfarin Warfarin results in increased expression of ABCB1A mRNA |
CTD |
PMID:24092646 PMID:25312789 PMID:27397090 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions increases response to substance |
ISO |
[Magnesium deficiency co-treated with Phosphates] promotes the reaction [ABCC6 gene mutant form results in increased susceptibility to Warfarin] |
CTD |
PMID:23415960 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects response to substance |
ISO |
ABCG2 SNP affects the susceptibility to Warfarin |
CTD |
PMID:25300812 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of ACTA2 mRNA |
CTD |
PMID:23117658 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
increases expression decreases expression |
ISO |
Warfarin results in increased expression of ACTB mRNA Warfarin results in decreased expression of ACTB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actr3 |
actin related protein 3 |
increases expression |
ISO |
Warfarin results in increased expression of ACTR3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression |
EXP |
Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of ADIPOQ protein] Warfarin results in increased expression of ADIPOQ protein |
CTD |
PMID:27488359 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 mRNA]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 protein] |
CTD |
PMID:36162953 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO |
Warfarin results in decreased expression of AHCY mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP inhibits the reaction [[Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein]; [Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein; [Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:22659116 PMID:27212383 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions affects binding decreases expression |
ISO EXP |
[Warfarin binds to ALB protein] inhibits the reaction [copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) binds to ALB protein]; [Warfarin binds to ALB protein] inhibits the reaction [copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex binds to ALB protein]; Aspirin inhibits the reaction [Warfarin binds to ALB protein]; prodan inhibits the reaction [Warfarin binds to ALB protein]; Pyruvaldehyde inhibits the reaction [Warfarin binds to ALB protein] Warfarin results in decreased expression of ALB protein |
CTD |
PMID:10506189 PMID:12044178 PMID:18937368 PMID:19596536 PMID:20934417 PMID:20956006 PMID:22342526 PMID:25499135 More...
|
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
ISO |
Warfarin results in increased expression of ALOX5AP mRNA |
CTD |
PMID:16698924 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
Warfarin results in decreased expression of ANXA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Warfarin results in decreased expression of ANXA5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apoa1 |
apolipoprotein A1 |
affects response to substance |
ISO |
APOA1 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:32282500 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
affects response to substance |
ISO |
APOB gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:31186542 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
increases response to substance affects response to substance |
ISO |
APOE gene mutant form results in increased susceptibility to Warfarin APOE gene mutant form affects the susceptibility to Warfarin; APOE gene polymorphism affects the susceptibility to Warfarin; APOE gene SNP affects the susceptibility to Warfarin; APOE polymorphism affects the susceptibility to Warfarin; APOE protein affects the susceptibility to Warfarin; APOE SNP affects the susceptibility to Warfarin |
CTD |
PMID:15952022 PMID:16847429 PMID:17048007 PMID:17325732 PMID:21228733 PMID:23415960 PMID:25312789 PMID:28079798 PMID:31854268 More...
|
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Warfarin results in increased expression of ARHGDIA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arsl |
arylsulfatase L |
decreases activity |
ISO |
Warfarin results in decreased activity of ARSL protein |
CTD |
PMID:7720070 |
|
NCBI chr 2:119,038,803...119,047,579
Ensembl chr 2:119,038,921...119,046,846
|
|
G |
Asph |
aspartate-beta-hydroxylase |
affects response to substance |
ISO |
ASPH gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488176 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Axin2 |
axin 2 |
multiple interactions increases expression |
EXP |
[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of AXIN2 mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Axl |
Axl receptor tyrosine kinase |
multiple interactions decreases phosphorylation increases response to substance decreases expression |
EXP ISO |
[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of AXL protein] Warfarin results in decreased phosphorylation of AXL protein AXL protein results in increased susceptibility to Warfarin AXL protein promotes the reaction [Warfarin results in increased susceptibility to Gemcitabine]; Vitamin K inhibits the reaction [Warfarin results in decreased expression of AXL protein modified form]; Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein] Warfarin results in decreased expression of AXL protein; Warfarin results in decreased expression of AXL protein modified form |
CTD |
PMID:15123721 PMID:26206560 PMID:27212383 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein] |
CTD |
PMID:27212383 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases expression |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [menaquinone 7 results in increased carboxylation of BGLAP protein]; Warfarin inhibits the reaction [menatetrenone results in increased carboxylation of BGLAP protein]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [Vitamin K 1 results in increased carboxylation of BGLAP protein] Warfarin results in increased expression of BGLAP mRNA; Warfarin results in increased expression of BGLAP protein modified form [Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of BGLAP protein modified form] |
CTD |
PMID:21910061 PMID:23117658 PMID:23223575 PMID:27488359 PMID:31173816 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein] |
CTD |
PMID:21910061 PMID:27412937 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
C1qbp |
complement C1q binding protein |
increases expression |
ISO |
Warfarin results in increased expression of C1QBP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
Warfarin results in increased expression of CALR mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calu |
calumenin |
decreases response to substance affects response to substance |
EXP ISO |
CALU protein results in decreased susceptibility to Warfarin CALU gene SNP affects the susceptibility to Warfarin; CALU polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:11641264 PMID:20200517 PMID:27632229 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Casp3 |
caspase 3 |
decreases expression increases expression multiple interactions |
ISO EXP |
Warfarin results in decreased expression of CASP3 mRNA Warfarin results in increased expression of CASP3 protein modified form [Warfarin co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein Warfarin results in increased expression of CASP3 mRNA |
CTD |
PMID:19815060 PMID:20493250 PMID:23990204 PMID:26206560 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity |
EXP |
Warfarin results in increased activity of CAT protein |
CTD |
PMID:22342526 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
EXP |
Warfarin results in increased expression of CCND1 mRNA [Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of CCND1 mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
increases expression |
ISO |
Warfarin results in increased expression of CCT5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
increases expression |
ISO |
Warfarin results in increased expression of CCT6A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
decreases expression |
ISO |
Warfarin results in decreased expression of CCT8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Warfarin results in decreased expression of CDC42 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Warfarin results in increased expression of CDH1 protein |
CTD |
PMID:26206560 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of CLIC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of CNN1 mRNA |
CTD |
PMID:23117658 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA] [Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of COL1A1 mRNA] |
CTD |
PMID:21910061 PMID:23117658 PMID:23223575 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cox15 |
cytochrome c oxidase assembly homolog COX15 |
affects response to substance |
ISO |
COX15 gene affects the susceptibility to Warfarin |
CTD |
PMID:28686080 |
|
NCBI chr 1:242,605,588...242,622,279
Ensembl chr 1:242,605,588...242,622,261
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
increases expression |
ISO |
Warfarin results in increased expression of COX5A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
increases expression |
ISO |
Warfarin results in increased expression of CRK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions affects response to substance |
ISO EXP |
Warfarin results in decreased expression of and affects the localization of CTNNB1 protein CTNNB1 protein affects the susceptibility to Warfarin Quercetin inhibits the reaction [Warfarin results in increased expression of and affects the localization of CTNNB1 protein]; Warfarin results in increased expression of and affects the localization of CTNNB1 protein |
CTD |
PMID:23117658 PMID:23223575 PMID:26206560 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing affects response to substance |
ISO |
CYP1A2 protein affects the metabolism of Warfarin CYP1A2 SNP affects the susceptibility to Warfarin |
CTD |
PMID:14676821 PMID:15280511 PMID:28079798 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases metabolic processing affects response to substance |
EXP ISO |
CYP2C11 protein results in increased metabolism of Warfarin CYP2C18 gene polymorphism affects the susceptibility to Warfarin; CYP2C18 protein affects the susceptibility to Warfarin |
CTD |
PMID:19752777 PMID:30724651 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
affects response to substance decreases activity affects metabolic processing multiple interactions |
ISO |
CYP2C19 gene polymorphism affects the susceptibility to Warfarin; CYP2C19 polymorphism affects the susceptibility to Warfarin; CYP2C19 protein affects the susceptibility to Warfarin Warfarin results in decreased activity of CYP2C29 protein CYP2C19 protein affects the metabolism of Warfarin CYP2C19 gene polymorphism affects the metabolism of and affects the susceptibility to Warfarin; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin] |
CTD |
PMID:18420780 PMID:18520598 PMID:19752777 PMID:25652102 PMID:27356304 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects response to substance |
ISO |
CYP2C8 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:34382722 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP2D6 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression affects hydroxylation multiple interactions decreases expression affects metabolic processing affects response to substance decreases activity |
EXP ISO |
Warfarin results in increased expression of CYP3A2 mRNA CYP3A4 protein affects the hydroxylation of Warfarin [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Warfarin results in decreased expression of CYP3A4 mRNA CYP3A4 protein affects the metabolism of Warfarin CYP3A4 SNP affects the susceptibility to Warfarin Warfarin results in decreased activity of CYP3A4 protein CYP3A2 mRNA affects the susceptibility to Warfarin |
CTD |
PMID:2271712 PMID:11531004 PMID:15280511 PMID:16035367 PMID:18420780 PMID:20735727 PMID:28079798 PMID:30963258 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects response to substance |
ISO |
CYP3A5 gene polymorphism affects the susceptibility to Warfarin; CYP3A5 polymorphism affects the susceptibility to Warfarin; CYP3A5 protein affects the susceptibility to Warfarin |
CTD |
PMID:19752777 PMID:34382722 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dctn2 |
dynactin subunit 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of DCTN2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Ddhd1 |
DDHD domain containing 1 |
affects response to substance |
ISO |
DDHD1 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488176 |
|
NCBI chr15:18,824,389...18,891,036
Ensembl chr15:18,824,394...18,890,952
|
|
G |
Ddt |
D-dopachrome tautomerase |
decreases expression |
ISO |
Warfarin results in decreased expression of DDT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
decreases expression |
ISO |
Warfarin results in decreased expression of DLST mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dock7 |
dedicator of cytokinesis 7 |
increases expression |
ISO |
Warfarin results in increased expression of DOCK7 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
ISO |
Warfarin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
decreases expression |
ISO |
Warfarin results in decreased expression of DSTN mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of EEF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Eif3i |
eukaryotic translation initiation factor 3, subunit I |
decreases expression |
ISO |
Warfarin results in decreased expression of EIF3I mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676
|
|
G |
Emcn |
endomucin |
decreases expression |
ISO |
Warfarin results in decreased expression of EMCN protein |
CTD |
PMID:26206560 |
|
NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
increases expression |
EXP |
Warfarin results in increased expression of ENPP1 mRNA; Warfarin results in increased expression of ENPP1 protein |
CTD |
PMID:22659116 |
|
NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715
|
|
G |
Epha7 |
Eph receptor A7 |
affects response to substance |
ISO |
EPHA7 promoter SNP affects the susceptibility to Warfarin |
CTD |
PMID:30357299 |
|
NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases response to substance affects response to substance |
ISO |
EPHX1 protein results in increased susceptibility to Warfarin EPHX1 gene polymorphism affects the susceptibility to Warfarin; EPHX1 gene SNP affects the susceptibility to Warfarin; EPHX1 intron SNP affects the susceptibility to Warfarin; EPHX1 polymorphism affects the susceptibility to Warfarin; EPHX1 SNP affects the susceptibility to Warfarin |
CTD |
PMID:15900282 PMID:17496169 PMID:20842355 PMID:21192345 PMID:24092646 PMID:27632229 PMID:28079798 More...
|
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
Warfarin results in decreased expression of ERP29 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
F10 |
coagulation factor X |
decreases activity |
EXP |
Warfarin results in decreased activity of F10 protein |
CTD |
PMID:3490277 PMID:20371969 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions decreases activity decreases expression affects response to substance |
ISO EXP |
Fenofibrate promotes the reaction [Warfarin results in decreased expression of F2 protein] Warfarin results in decreased activity of F2 protein F2 gene polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:3490277 PMID:9681093 PMID:14656880 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
affects response to substance decreases activity |
ISO EXP |
F5 gene polymorphism affects the susceptibility to Warfarin; F5 protein affects the susceptibility to Warfarin Warfarin results in decreased activity of F5 protein |
CTD |
PMID:3490277 PMID:19752777 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
F7 |
coagulation factor VII |
affects response to substance decreases activity multiple interactions decreases expression |
ISO EXP |
F7 gene mutant form affects the susceptibility to Warfarin; F7 gene polymorphism affects the susceptibility to Warfarin Warfarin results in decreased activity of F7 protein Fenofibrate promotes the reaction [Warfarin results in decreased expression of F7 protein] |
CTD |
PMID:3490277 PMID:9681093 PMID:14656880 PMID:20371969 PMID:20885134 |
|
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
|
|
G |
F9 |
coagulation factor IX |
decreases activity increases response to substance |
EXP ISO |
Warfarin results in decreased activity of F9 protein F9 gene alternative form results in increased susceptibility to Warfarin |
CTD |
PMID:3490277 PMID:29450643 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
EXP |
Warfarin inhibits the reaction [3-(p-azidobenzyl)-4-hydroxycoumarin binds to Fabp1 protein] |
RGD |
PMID:1939124 |
RGD:1626448 |
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
affects response to substance |
ISO |
FGF5 gene affects the susceptibility to Warfarin |
CTD |
PMID:28686080 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fpgs |
folylpolyglutamate synthase |
affects response to substance |
ISO |
FPGS gene polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:25079360 |
|
NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of FSCN1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
increases expression |
ISO |
Warfarin results in increased expression of G3BP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
Gal3st1 |
galactose-3-O-sulfotransferase 1 |
increases expression |
ISO |
Warfarin results in increased expression of GAL3ST1 mRNA |
CTD |
PMID:27397090 |
|
NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388
|
|
G |
Gale |
UDP-galactose-4-epimerase |
decreases expression |
ISO |
Warfarin results in decreased expression of GALE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gas6 |
growth arrest specific 6 |
decreases expression multiple interactions decreases carboxylation |
EXP ISO |
Warfarin results in decreased expression of GAS6 protein Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein] Warfarin results in decreased carboxylation of GAS6 protein [Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein]; Warfarin results in decreased activity of and results in decreased carboxylation of GAS6 protein |
CTD |
PMID:9163328 PMID:19564549 PMID:26206560 PMID:27212383 |
|
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
|
|
G |
Gata4 |
GATA binding protein 4 |
affects response to substance |
ISO |
GATA4 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:31190750 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gata6 |
GATA binding protein 6 |
affects response to substance |
ISO |
GATA6 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:31190750 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
increases expression |
ISO |
Warfarin results in increased expression of GDI2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
Warfarin results in increased expression of GFAP mRNA; Warfarin results in increased expression of GFAP protein |
CTD |
PMID:27397090 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ggcx |
gamma-glutamyl carboxylase |
affects response to substance increases activity increases response to substance decreases response to substance |
ISO EXP |
GGCX gene polymorphism affects the susceptibility to Warfarin; GGCX gene SNP affects the susceptibility to Warfarin; GGCX polymorphism affects the susceptibility to Warfarin Warfarin results in increased activity of GGCX protein GGCX protein results in increased susceptibility to Warfarin GGCX gene polymorphism results in decreased susceptibility to Warfarin |
CTD |
PMID:3490277 PMID:16676068 PMID:17049586 PMID:17496169 PMID:17764537 PMID:21195460 PMID:21326313 PMID:22161100 PMID:25042728 PMID:27632229 More...
|
|
NCBI chr 4:104,469,737...104,485,631
Ensembl chr 4:104,469,765...104,487,063
|
|
G |
Gmps |
guanine monophosphate synthase |
increases expression |
ISO |
Warfarin results in increased expression of GMPS mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875
|
|
G |
Gprc6a |
G protein-coupled receptor, class C, group 6, member A |
multiple interactions |
EXP |
Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GPRC6A mRNA] |
CTD |
PMID:27488359 |
|
NCBI chr20:30,922,106...30,943,412
Ensembl chr20:30,922,106...30,943,412
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:23117658 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hdac1 |
histone deacetylase 1 |
increases expression |
ISO |
Warfarin results in increased expression of HDAC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] |
CTD |
PMID:36162953 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
increases expression |
ISO |
Warfarin results in increased expression of HINT1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of HMGCR mRNA] |
CTD |
PMID:27488359 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression |
EXP |
Warfarin affects the expression of HMOX1 mRNA |
CTD |
PMID:22954530 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
increases expression |
ISO |
Warfarin results in increased expression of HNRNPAB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
decreases expression |
ISO |
Warfarin results in decreased expression of HNRNPDL mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506
|
|
G |
Hnrnpf |
heterogeneous nuclear ribonucleoprotein F |
increases expression |
ISO |
Warfarin results in increased expression of HNRNPF mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
increases expression decreases expression |
ISO |
Warfarin results in increased expression of HNRNPK mRNA Warfarin results in decreased expression of HNRNPK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hp |
haptoglobin |
increases expression |
EXP |
Warfarin results in increased expression of HP protein |
CTD |
PMID:22342526 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
Warfarin results in increased expression of HSPA8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
Warfarin results in increased expression of HSPD1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Il12a |
interleukin 12A |
increases expression |
EXP |
Warfarin results in increased expression of IL12A mRNA |
CTD |
PMID:22342526 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
increases expression |
EXP |
Warfarin results in increased expression of IL12B mRNA |
CTD |
PMID:22342526 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
Warfarin inhibits the reaction [Vitamin K 2 results in decreased susceptibility to IL1B protein] Warfarin results in decreased expression of IL1B mRNA [Warfarin co-treated with Vitamin K] results in increased expression of IL1B mRNA |
CTD |
PMID:20460758 PMID:23117658 PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Warfarin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions decreases expression decreases secretion |
EXP ISO |
Warfarin results in increased expression of IL6 protein [Warfarin co-treated with Vitamin K] results in increased expression of IL6 mRNA Warfarin results in decreased expression of IL6 mRNA Warfarin results in decreased secretion of IL6 protein Warfarin results in decreased expression of IL6 protein |
CTD |
PMID:18772604 PMID:22342526 PMID:23117658 PMID:26742017 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
increases secretion multiple interactions |
EXP |
Warfarin results in increased secretion of INS1 protein Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased secretion of INS1 protein] |
CTD |
PMID:27488359 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ipo5 |
importin 5 |
decreases expression |
ISO |
Warfarin results in decreased expression of IPO5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
ISO |
Warfarin results in increased expression of ISYNA1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Krt18 |
keratin 18 |
decreases expression |
ISO |
Warfarin results in decreased expression of KRT18 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of LASP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
affects response to substance |
ISO |
LRP1 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:32282500 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36162953 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36162953 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgp |
matrix Gla protein |
multiple interactions decreases carboxylation |
ISO EXP |
[[Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein] which results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased expression of MGP mRNA Warfarin results in decreased carboxylation of MGP protein [Quercetin co-treated with Warfarin] results in decreased carboxylation of MGP protein; [Vitamin K co-treated with Warfarin] results in increased carboxylation of MGP protein; Warfarin inhibits the reaction [Vitamin K 1 results in increased expression of and results in increased secretion of MGP protein modified form]; Warfarin results in decreased expression of and results in decreased secretion of MGP protein; Warfarin results in decreased expression of and results in decreased secretion of MGP protein modified form |
CTD |
PMID:21705322 PMID:23223575 PMID:23990204 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mir3582 |
microRNA 3582 |
affects response to substance |
ISO |
MIR133A2 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:26113018 |
|
NCBI chr18:1,885,063...1,885,180
Ensembl chr18:1,885,063...1,885,180
|
|
G |
Mpo |
myeloperoxidase |
increases activity |
EXP |
Warfarin results in increased activity of MPO protein |
CTD |
PMID:26742017 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myh1 |
myosin heavy chain 1 |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of MYH1 mRNA |
CTD |
PMID:23117658 |
|
NCBI chr10:51,885,913...51,909,699
Ensembl chr10:51,885,913...51,946,295
|
|
G |
Myh6 |
myosin heavy chain 6 |
affects response to substance |
ISO |
MYH6 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:34515533 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
affects response to substance |
ISO |
NEDD4 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488176 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nmral1 |
NmrA like redox sensor 1 |
increases expression |
ISO |
Warfarin results in increased expression of NMRAL1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
affects response to substance |
ISO |
NQO1 gene SNP affects the susceptibility to Warfarin; NQO1 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:23215885 PMID:26257249 PMID:27581200 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions decreases expression |
ISO |
[Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA; [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Warfarin binds to and results in increased activity of NR1I2 protein Warfarin results in decreased expression of NR1I2 mRNA |
CTD |
PMID:20735727 PMID:30963258 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nucb1 |
nucleobindin 1 |
increases expression |
ISO |
Warfarin results in increased expression of NUCB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
|
|
G |
Oat |
ornithine aminotransferase |
decreases expression |
ISO |
Warfarin results in decreased expression of OAT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions affects binding increases response to substance affects response to substance |
ISO |
Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Dipyridamole inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Lidocaine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Progesterone inhibits the reaction [Warfarin binds to ORM1 protein alternative form] ORM1 protein results in increased susceptibility to Warfarin ORM1 gene polymorphism affects the susceptibility to Warfarin; ORM1 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:8946472 PMID:17496169 PMID:23208322 PMID:26644206 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
increases expression |
ISO |
Warfarin results in increased expression of PA2G4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression |
ISO |
Warfarin results in increased expression of PARP1 protein modified form |
CTD |
PMID:26206560 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
EXP |
Warfarin results in decreased expression of PDGFB mRNA; Warfarin results in decreased expression of PDGFB protein |
CTD |
PMID:11290560 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
increases expression decreases expression |
ISO |
Warfarin results in increased expression of PDIA3 mRNA Warfarin results in decreased expression of PDIA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Warfarin results in decreased expression of PDIA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
decreases expression increases expression |
ISO |
Warfarin results in decreased expression of PGAM1 mRNA Warfarin results in increased expression of PGAM1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pkm |
pyruvate kinase M1/2 |
decreases expression |
ISO |
Warfarin results in decreased expression of PKM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plp1 |
proteolipid protein 1 |
increases expression |
ISO |
Warfarin results in increased expression of PLP1 mRNA |
CTD |
PMID:27397090 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Por |
cytochrome p450 oxidoreductase |
affects response to substance |
ISO |
POR gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488389 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
ISO |
Warfarin results in decreased expression of PPP1CA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
ISO |
Warfarin results in increased expression of PPP2R1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Proc |
protein C, inactivator of coagulation factors Va and VIIIa |
increases response to substance affects response to substance |
ISO |
PROC protein results in increased susceptibility to Warfarin PROC gene polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:17048007 PMID:17496169 |
|
NCBI chr18:23,764,367...23,774,816
Ensembl chr18:23,764,368...23,775,133
|
|
G |
Pros1 |
protein S |
affects response to substance |
ISO |
PROS1 gene polymorphism affects the susceptibility to Warfarin; PROS1 protein affects the susceptibility to Warfarin |
CTD |
PMID:19752777 |
|
NCBI chr11:230,597...311,288
Ensembl chr11:230,696...311,286
|
|
G |
Prss53 |
serine protease 53 |
affects response to substance |
ISO |
PRSS53 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:21590310 |
|
NCBI chr 1:182,494,944...182,501,607
Ensembl chr 1:182,494,955...182,500,115
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
decreases expression |
ISO |
Warfarin results in decreased expression of PSMA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Psma6 |
proteasome 20S subunit alpha 6 |
decreases expression |
ISO |
Warfarin results in decreased expression of PSMA6 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554
|
|
G |
Psmc2 |
proteasome 26S subunit, ATPase 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of PSMC2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
|
|
G |
Pth |
parathyroid hormone |
decreases activity |
ISO |
Warfarin results in decreased activity of PTH protein |
CTD |
PMID:11564701 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Rab1a |
RAB1A, member RAS oncogene family |
decreases expression |
ISO |
Warfarin results in decreased expression of RAB1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
ISO |
Warfarin results in decreased expression of RHOA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl27 |
ribosomal protein L27 |
increases expression |
ISO |
Warfarin results in increased expression of RPL27 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
|
|
G |
Rpl9 |
ribosomal protein L9 |
increases expression |
ISO |
Warfarin results in increased expression of RPL9 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136 Ensembl chr 3:42,893,942...42,897,136 Ensembl chr 1:42,893,942...42,897,136
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Warfarin results in increased expression of RPLP0 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RPS6KB1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:36162953 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rpsa |
ribosomal protein SA |
increases expression |
ISO |
Warfarin results in increased expression of RPSA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
increases expression multiple interactions |
EXP |
Warfarin results in increased expression of RUNX1 mRNA Quercetin inhibits the reaction [Warfarin results in increased expression of RUNX1 mRNA] |
CTD |
PMID:23223575 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein; [Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:21910061 PMID:23117658 PMID:27412937 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of RUVBL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of SAE1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Sephs1 |
selenophosphate synthetase 1 |
increases expression |
ISO |
Warfarin results in increased expression of SEPHS1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593
|
|
G |
Serpinc1 |
serpin family C member 1 |
increases expression |
ISO |
Warfarin results in increased expression of SERPINC1 protein |
CTD |
PMID:73932 |
|
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
affects response to substance |
ISO |
SLC15A2 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:29234073 |
|
NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
affects response to substance |
ISO |
SLCO1B3 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:29234073 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sost |
sclerostin |
affects response to substance |
ISO |
SOST affects the susceptibility to Warfarin |
CTD |
PMID:35038187 |
|
NCBI chr10:86,912,517...86,915,561
Ensembl chr10:86,911,517...86,915,561
|
|
G |
Sox5 |
SRY-box transcription factor 5 |
affects localization decreases expression |
ISO |
Warfarin affects the localization of SOX5 protein Warfarin results in decreased expression of SOX5 mRNA; Warfarin results in decreased expression of SOX5 protein |
CTD |
PMID:34520801 |
|
NCBI chr 4:176,781,375...177,736,833
Ensembl chr 4:176,785,892...177,736,852
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
affects localization multiple interactions |
ISO |
Warfarin affects the localization of SOX9 protein leptomycin B inhibits the reaction [Warfarin affects the localization of SOX9 protein] |
CTD |
PMID:34520801 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO EXP |
[Warfarin co-treated with Vitamin K 1] results in increased expression of SPP1 mRNA [Quercetin co-treated with Warfarin] results in increased expression of SPP1 mRNA; [Warfarin co-treated with Vitamin K] results in increased expression of SPP1 mRNA |
CTD |
PMID:23117658 PMID:23223575 PMID:23990204 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of STIP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Tagln |
transgelin |
multiple interactions |
ISO EXP |
[Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA |
CTD |
PMID:23117658 PMID:23990204 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tcf4 |
transcription factor 4 |
increases expression multiple interactions |
EXP |
Warfarin results in increased expression of TCF4 mRNA [Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of TCF4 mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
|
|
G |
Tcp1 |
t-complex 1 |
increases expression |
ISO |
Warfarin results in increased expression of TCP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839
|
|
G |
Tgm2 |
transglutaminase 2 |
affects response to substance multiple interactions increases response to substance |
ISO EXP |
[TGM2 protein affects the susceptibility to Warfarin] which affects the susceptibility to Quercetin; TGM2 protein affects the susceptibility to Warfarin [Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein]; Quercetin inhibits the reaction [Warfarin results in increased activity of TGM2 protein]; Warfarin results in increased expression of and results in increased activity of TGM2 protein TGM2 protein results in increased susceptibility to Warfarin |
CTD |
PMID:23117658 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Thop1 |
thimet oligopeptidase 1 |
increases expression |
ISO |
Warfarin results in increased expression of THOP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,632,911...8,645,339
Ensembl chr 7:8,632,916...8,645,275
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases expression multiple interactions decreases secretion |
EXP |
Warfarin results in decreased expression of TNF mRNA Warfarin results in increased expression of TNF [Warfarin co-treated with Vitamin K] results in increased expression of TNF mRNA Warfarin results in decreased secretion of TNF protein |
CTD |
PMID:21565690 PMID:22342526 PMID:23117658 PMID:26742017 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases degradation increases expression |
ISO |
Warfarin results in increased degradation of TP53 protein Warfarin results in increased expression of TRP53 mRNA; Warfarin results in increased expression of TRP53 protein |
CTD |
PMID:14634213 PMID:29358327 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
ISO |
Warfarin results in increased expression of TUBA1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tuba1b |
tubulin, alpha 1B |
decreases expression increases expression |
ISO |
Warfarin results in decreased expression of TUBA1B mRNA Warfarin results in increased expression of TUBA1B mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
decreases expression |
ISO |
Warfarin results in decreased expression of TUBB5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
Warfarin results in decreased expression of TUFM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
Tyro3 |
TYRO3 protein tyrosine kinase |
decreases expression |
ISO |
Warfarin results in decreased expression of TYRO3 mRNA |
CTD |
PMID:18772604 PMID:27397090 |
|
NCBI chr 3:106,777,686...106,797,154
Ensembl chr 3:106,777,635...106,797,142
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
increases expression |
ISO |
Warfarin results in increased expression of U2AF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions affects response to substance increases metabolic processing |
ISO |
[UGT1A1 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of Glucuronides; [Warfarin binds to and results in decreased activity of UGT1A1 protein] which results in decreased glucuronidation of Estradiol; Warfarin binds to and results in decreased activity of UGT1A1 protein; Warfarin inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Estradiol] UGT1A1 gene SNP affects the susceptibility to Warfarin; UGT1A1 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:19408964 PMID:25312789 PMID:25393417 PMID:26223945 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions |
ISO |
[Warfarin binds to and results in increased activity of UGT1A3 protein] which results in increased glucuronidation of vorinostat; Warfarin binds to and results in increased activity of UGT1A3 protein; Warfarin promotes the reaction [UGT1A3 protein results in increased glucuronidation of vorinostat] |
CTD |
PMID:25393417 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
ISO |
[Warfarin binds to and affects the activity of UGT1A9 protein] which affects the glucuronidation of Propofol; Warfarin affects the reaction [UGT1A9 protein results in increased glucuronidation of Propofol]; Warfarin binds to and affects the activity of UGT1A9 protein |
CTD |
PMID:25393417 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
multiple interactions |
ISO |
[Warfarin binds to and results in decreased activity of UGT2B17 protein] which results in decreased glucuronidation of vorinostat; Warfarin binds to and results in decreased activity of UGT2B17 protein; Warfarin inhibits the reaction [UGT2B17 protein results in increased glucuronidation of vorinostat] |
CTD |
PMID:25393417 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
[Warfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine; Warfarin binds to and results in decreased activity of UGT2B7 protein; Warfarin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Zidovudine] |
CTD |
PMID:25393417 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 |
decreases expression |
ISO |
Warfarin results in decreased expression of USP5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711
|
|
G |
Vcp |
valosin-containing protein |
decreases expression increases expression |
ISO |
Warfarin results in decreased expression of VCP mRNA Warfarin results in increased expression of VCP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
G |
Vdr |
vitamin D receptor |
affects response to substance |
ISO |
VDR gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:28262345 PMID:29298995 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects response to substance multiple interactions |
ISO |
VEGFA gene SNP affects the susceptibility to Warfarin epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA mRNA]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA protein] |
CTD |
PMID:31068094 PMID:36162953 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
Warfarin results in decreased expression of VIM protein |
CTD |
PMID:26206560 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
multiple interactions decreases activity affects abundance decreases response to substance affects response to substance affects metabolic processing increases response to substance decreases metabolic processing |
ISO EXP |
[CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin; Warfarin binds to and results in decreased activity of VKORC1 protein; Warfarin inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide] Warfarin results in decreased activity of VKORC1 protein VKORC1 gene polymorphism affects the abundance of Warfarin VKORC1 3' UTR results in decreased susceptibility to Warfarin; VKORC1 gene mutant form results in decreased susceptibility to Warfarin; VKORC1 gene polymorphism results in decreased susceptibility to Warfarin VKORC1 3' UTR SNP affects the susceptibility to Warfarin; VKORC1 affects the susceptibility to Warfarin; VKORC1 alternative form affects the susceptibility to Warfarin; VKORC1 gene affects the susceptibility to Warfarin; VKORC1 gene mutant form affects the susceptibility to Warfarin; VKORC1 gene polymorphism affects the susceptibility to Warfarin; VKORC1 gene SNP affects the susceptibility to Warfarin; VKORC1 intron polymorphism affects the susceptibility to Warfarin; VKORC1 intron SNP affects the susceptibility to Warfarin; VKORC1 polymorphism affects the susceptibility to Warfarin; VKORC1 promoter polymorphism affects the susceptibility to Warfarin; VKORC1 promoter SNP affects the susceptibility to Warfarin; VKORC1 protein affects the susceptibility to Warfarin; VKORC1 protein polymorphism affects the susceptibility to Warfarin; VKORC1 protein SNP affects the susceptibility to Warfarin; VKORC1 SNP affects the susceptibility to Warfarin Warfarin inhibits the reaction [VKORC1 protein affects the reduction of vitamin K1 oxide] VKORC1 gene mutant form results in decreased susceptibility to Warfarin; VKORC1 protein polymorphism results in decreased susceptibility to Warfarin VKORC1 protein mutant form affects the susceptibility to Warfarin VKORC1 protein affects the metabolism of Warfarin VKORC1 intron polymorphism results in increased susceptibility to Warfarin; VKORC1 protein results in increased susceptibility to Warfarin; VKORC1 results in increased susceptibility to Warfarin VKORC1 gene polymorphism results in decreased metabolism of Warfarin |
CTD |
PMID:14765194 PMID:14765195 PMID:15358623 PMID:15578879 PMID:15630486 PMID:15879509 PMID:15930419 PMID:16270629 PMID:16421894 PMID:16432637 PMID:16611750 PMID:16676068 PMID:16847429 PMID:16879214 PMID:16890578 PMID:16960144 PMID:17048007 PMID:17049586 PMID:17111199 PMID:17329985 PMID:17387222 PMID:17391071 PMID:17456829 PMID:17496169 PMID:17510308 PMID:17764537 PMID:17941040 PMID:17961434 PMID:17995970 PMID:18030307 PMID:18034619 PMID:18240904 PMID:18266023 PMID:18370846 PMID:18523153 PMID:18532998 PMID:18535201 PMID:18542936 PMID:18574025 PMID:18698879 PMID:18776969 PMID:18805772 PMID:19018718 PMID:19135231 PMID:19200363 PMID:19207028 PMID:19300499 PMID:19567378 PMID:19752777 PMID:19942260 PMID:19998810 PMID:20072124 PMID:20073138 PMID:20339978 PMID:20354686 PMID:20375999 PMID:20386359 PMID:20420818 PMID:20553802 PMID:20579077 PMID:20615525 PMID:20637959 PMID:20716240 PMID:20833655 PMID:20842355 PMID:20854800 PMID:21084764 PMID:21110192 PMID:21176721 PMID:21228733 PMID:21270790 PMID:21320153 PMID:21321468 PMID:21326313 PMID:21428138 PMID:21562147 PMID:21590310 PMID:21635147 PMID:21639946 PMID:21681008 PMID:21786578 PMID:21911247 PMID:22040439 PMID:22161100 PMID:22198820 PMID:22248286 PMID:22266406 PMID:22528326 PMID:22533669 PMID:22571356 PMID:22855348 PMID:22907842 PMID:22990331 PMID:23018795 PMID:23061746 PMID:23167228 PMID:23183958 PMID:23208322 PMID:23276529 PMID:23279643 PMID:23571513 PMID:23602689 PMID:23710884 PMID:23800980 PMID:23928358 PMID:23990957 PMID:24399734 PMID:24474498 PMID:24601977 PMID:24750390 PMID:24966969 PMID:24978953 PMID:25042728 PMID:25312789 PMID:25652102 PMID:25699611 PMID:25747538 PMID:25885753 PMID:25946405 PMID:25986145 PMID:26167638 PMID:26219158 PMID:26223945 PMID:26257249 PMID:26418980 PMID:26445138 PMID:26568290 PMID:26583785 PMID:26644206 PMID:26757860 PMID:26940072 PMID:26996562 PMID:27055637 PMID:27117082 PMID:27258224 PMID:27262824 PMID:27488176 PMID:27622442 PMID:27632229 PMID:27743182 PMID:27938396 PMID:28079798 PMID:28083852 PMID:28135054 PMID:28262345 PMID:28401802 PMID:28550460 PMID:28686080 PMID:28689179 PMID:28867752 PMID:29182754 PMID:29234073 PMID:29581108 PMID:29776386 PMID:30647445 PMID:30883300 PMID:31064211 PMID:31173123 PMID:31395958 PMID:31720756 PMID:31854268 PMID:31869433 PMID:31973625 PMID:32219822 PMID:32669629 PMID:34382722 PMID:34729928 PMID:36476275 PMID:36789833 More...
|
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
multiple interactions |
ISO EXP |
Warfarin affects the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide]; Warfarin binds to and results in decreased activity of VKORC1L1 protein; Warfarin inhibits the reaction [VKORC1L1 protein results in increased metabolism of vitamin K1 oxide]; Warfarin inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide] |
CTD |
PMID:23710884 PMID:23928358 PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
G |
Ywhae |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon |
increases expression |
ISO |
Warfarin results in increased expression of YWHAE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of ZEB1 protein |
CTD |
PMID:26206560 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|